In short
Clinical trials are studying Semaglutide in many different health conditions, from type 2 diabetes and obesity to kidney disease, heart disease, and other disorders. These studies look at how well it works, how safe it is in different groups, and which patients may benefit most. Some trials compare it with placebo, standard care, or other medicines.
Key points
- Clinical trials of Semaglutide are being done in many groups, including people with type 2 diabetes, obesity, chronic kidney disease, heart and blood vessel disease, and some younger patients. Most studies are Phase 2 or Phase 3, so they are testing both how well the treatment works and how safe it is in larger groups. The main outcomes often include HbA1c, body weight, BMI, kidney markers like UACR, and heart-related events. Some trials also study special areas such as stroke recovery, fertility, diabetic foot ulcers, liver disease, and mental health-related weight gain. Several studies compare Semaglutide with placebo, while others compare it with standard care or other medicines. A few trials are completed, some are authorised, and a small number were withdrawn.
Clinical trials overview
These studies investigate Semaglutide in many different settings, often as an add-on to standard care or compared with placebo. The trial data include studies in chronic kidney disease, type 2 diabetes, obesity, heart and blood vessel disease, stroke, infertility, liver disease, and several other conditions.
Many trials are designed to see whether Semaglutide improves a main outcome such as blood sugar, body weight, kidney markers, or disease-specific measures. Several studies also look at safety, tolerability, and whether treatment works better than placebo or another active treatment.
Conditions being studied
Type 2 diabetes is the most common condition in the dataset, and it appears in many adult and pediatric studies. These trials often measure HbA1c, which is a blood test showing average blood sugar over time.
Obesity is another major research area, including studies in adults, adolescents, children, and people with obesity plus other health problems such as atrial fibrillation, resistant hypertension, heart failure, HIV, or sleep apnea. Several obesity trials measure body weight, BMI, or percent weight loss as the main result.
Chronic kidney disease is studied in more than one trial, including studies that measure urine albumin-to-creatinine ratio, also called UACR, and estimated kidney function decline. Some kidney studies include people with type 2 diabetes, obesity, or both, while others include chronic kidney disease more broadly.
There are also trials in cardiovascular disease, coronary artery disease, stroke, glaucoma, Alzheimer’s disease, alcohol use disorder, cannabis use disorder, and diabetic foot ulcer. This shows that Semaglutide is being studied far beyond weight and glucose control in the trial program.
Who can take part
The target populations vary widely across studies. Some trials include adults with type 2 diabetes, while others focus on children, teenagers, or young adults with obesity.
Several studies include people with extra health risks, such as overweight or obesity plus heart disease, prediabetes, kidney disease, or treatment with antipsychotic medicines. Some trials also have very specific groups, such as people with schizophrenia taking clozapine or olanzapine, women with prior gestational diabetes, or patients after kidney transplant.
A few studies are in children or adolescents with obesity, including those with hypothalamic obesity secondary to craniopharyngioma or obesity linked to antipsychotic treatment. Other studies focus on adults with conditions such as atrial fibrillation, resistant hypertension, or diabetic neuropathy.
Trial phases and study design
Most of the Semaglutide trials in the data are Phase 2 or Phase 3 studies. Phase 2 trials usually explore whether the treatment may work and continue to watch for safety, while Phase 3 trials are larger and are used to confirm benefit more strongly.
There are also some Phase 1 studies, such as the oral Semaglutide and dapagliflozin combination study in healthy participants. In that setting, the main goal is to understand how the medicines behave in the body when given together.
A few studies are listed as low intervention, which means the research uses limited extra intervention beyond routine care or simple study procedures. Several trials are randomized, placebo-controlled, or open-label, depending on the question being asked.
Main endpoints being measured
The most common endpoint in the trial data is change in HbA1c, especially in type 2 diabetes studies. This endpoint is used to see whether blood sugar control improves over time.
Weight-related studies often measure change in body weight, BMI, or percent total weight loss. Some studies also use thresholds such as achieving at least 5% weight loss or maintaining BMI below an obesity threshold.
Kidney studies often use UACR or chronic eGFR slope, which is the rate of long-term kidney function change. Heart and blood vessel studies may measure major adverse cardiovascular events, blood pressure, rhythm outcomes, or plaque changes on heart imaging.
Some trials use more specialized endpoints, such as modified Rankin Scale after stroke, good quality blastocysts in IVF, wound closure in diabetic foot ulcer, or gene expression in Alzheimer’s disease. These endpoints show that the studies are asking very different clinical questions, not only weight or glucose questions.
Special and less common research areas
Several trials explore Semaglutide in areas that are not the usual diabetes or obesity setting. For example, some studies look at diabetic retinopathy, glaucoma, multiple sclerosis, depression, alcohol use disorder, cannabis use disorder, and chemsex-related drug craving.
Other studies focus on inflammation, endothelial biomarkers, bone turnover, platelet reactivity, liver fat, or hepatic fibrosis. These are all biological signs that may help explain whether the treatment changes disease activity, not just symptoms.
Some trial titles also mention combination approaches, such as CagriSema, IcoSema, or Semaglutide with other medicines like finerenone or dapagliflozin. In these studies, Semaglutide is being tested as part of a broader treatment strategy rather than alone.
What these trials may help answer
Together, the studies ask where Semaglutide may help most, which patient groups may benefit, and which outcomes improve first. They also compare different doses, different formulations, and different combinations with other treatments.
The data show that research on Semaglutide is broad and still ongoing, with many authorised trials and several completed studies already available. The overall focus is on real clinical results that matter to patients, such as blood sugar, weight, kidney health, heart outcomes, and quality of life.